LM-102 / LaNova Medicines Limited - LARVOL DELTA

Study of LM-102 in Patients With Advance Solid Tumors (clinicaltrials.gov) - P1/2 | N=11 | Terminated | Sponsor: LaNova Medicines Development Co., Ltd. | N=265 ➔ 11 | Trial completion date: Jun 2025 ➔ Feb 2023 | Recruiting ➔ Terminated | Trial primary completion date: Mar 2025 ➔ Feb 2023; company adjusted strategy

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Oncology • Solid Tumor • CLDN18

Study of LM-102 in Subjects in Advanced Tumors (clinicaltrials.gov) - P1 | N=9 | Terminated | Sponsor: LaNova Medicines Limited | N=30 ➔ 9 | Trial completion date: Mar 2023 ➔ May 2022 | Recruiting ➔ Terminated | Trial primary completion date: Mar 2023 ➔ May 2022; Business strategy changed

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Biliary Tract Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Solid Tumor • CLDN18

Study of LM-102 in Patients With Advance Solid Tumors (clinicaltrials.gov) - P1/2; N=265; Recruiting; Sponsor: LaNova Medicines Development Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Monotherapy • Oncology • Solid Tumor • CLDN18

Study of LM-102 in Patients With Advance Solid Tumors (clinicaltrials.gov) - P1/2; N=265; Not yet recruiting; Sponsor: LaNova Medicines Development Co., Ltd.

New P1/2 trial • Oncology • Solid Tumor • CLDN18